Logo

EXOZ

eXoZymes, Inc.

EXOZ

eXoZymes, Inc. • NASDAQ
$15.87 ▲ 3.66% (+0.56)
Market Cap $133.11 M
52w High $23.99
52w Low $8.86
Dividend Yield 0%
P/E -15.87
Volume 875
Outstanding Shares 8.39M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.451M ▼ $-2.287M ▲ 0% $-0.27 ▲ $-2.215M ▲
Q2-2025 $0 $2.476M ▲ $-2.36M ▼ 0% $-0.28 ▼ $-2.288M ▼
Q1-2025 $0 $1.88M ▼ $-1.856M ▼ 0% $-0.22 ▲ $-1.88M ▼
Q4-2024 $0 $1.916M ▲ $-1.836M ▼ 0% $-0.45 ▼ $-1.771M ▼
Q3-2024 $0 $1.543M $-1.656M 0% $-0.2 $-1.543M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.099M ▼ $7.719M ▼ $2.345M ▼ $5.374M ▼
Q2-2025 $6.986M ▼ $9.677M ▼ $2.441M ▼ $7.236M ▼
Q1-2025 $8.511M ▼ $11.526M ▼ $2.644M ▲ $8.882M ▼
Q4-2024 $9.719M ▲ $13.034M ▲ $2.614M ▼ $10.421M ▲
Q3-2024 $233.935K $3.56M $7.162M $-3.601M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.287M ▲ $-1.857M ▼ $-13.308K ▲ $-17.155K ▼ $-1.887M ▼ $-1.87M ▼
Q2-2025 $-2.36M ▼ $-1.538M ▼ $-30.874K ▲ $43.254K ▲ $-1.526M ▼ $-1.589M ▼
Q1-2025 $-1.856M ▼ $-1.134M ▲ $-31.046K ▲ $-43.254K ▼ $-1.208M ▼ $-1.165M ▲
Q4-2024 $-1.836M ▼ $-5.708M ▼ $-210.407K ▼ $15.403M ▲ $9.485M ▲ $-5.918M ▼
Q3-2024 $-1.656M $-541.524K $30.857K $586.363K $75.696K $-541.524K

Five-Year Company Overview

Income Statement

Income Statement eXoZymes is a very early-stage, pre-revenue biotech company. It has not yet generated product or licensing revenue, and all reported losses come from operating expenses, mainly research, development, and corporate setup costs. Earnings per share have been negative for several years, which is typical for a young biotech still building its technology platform and pipeline. The income statement today is about investment and spending, not yet about commercial performance.

Balance Sheet

Balance Sheet The balance sheet is small and simple. The company holds a modest cash position and minimal other assets, with no reported debt. Equity essentially mirrors its cash base, reflecting that the business has been funded by shareholders rather than borrowing. This “clean” balance sheet reduces financial strain from interest payments but also highlights that the company is still very lean and dependent on future funding or partnerships as it grows.

Cash Flow

Cash Flow Cash flows are negative from operations, driven by research, staffing, and general overhead, with very limited spending on physical assets so far. In practical terms, money is flowing out to build the platform and pipeline, with nothing yet flowing in from customers. This is consistent with a pre-commercial biotech model, but it means the company’s runway and future financing needs are critical watch-points.

Competitive Edge

Competitive Edge eXoZymes is trying to carve out a niche at the intersection of synthetic biology, enzyme engineering, and artificial intelligence. Its cell-free enzyme platform aims to avoid many of the bottlenecks of traditional fermentation, which could be a meaningful edge if it scales as promised. The focus on high-value molecules and a licensing-heavy, capital-light model can be attractive from a strategic perspective. However, competition in biomanufacturing and AI-driven biology is intense, with both startups and large incumbents pursuing similar themes, so execution, partnerships, and proof of cost advantage will matter greatly.

Innovation and R&D

Innovation and R&D Innovation is clearly the centerpiece of this company. The platform relies on AI-designed enzymes that operate outside living cells, which is a distinctive scientific angle. Peer-reviewed publications and the creation of a focused subsidiary (NCTx) suggest real technical depth and a willingness to turn individual molecules into separate commercial vehicles. The model is R&D-heavy and highly experimental by nature: success depends on repeatedly engineering new enzyme systems, proving they work in industrial settings, and convincing partners to adopt them. The IP portfolio and trade secrets are important to protecting that effort over time.

Summary

eXoZymes is a very early-stage, pre-revenue biotech platform company built around AI-engineered, cell-free enzymes. Financially, it is in the investment and build-out phase: no revenues yet, operating losses, a small but clean balance sheet, and negative cash flow driven by R&D. Strategically, it is aiming for a capital-light licensing model targeting high-value chemical and life science markets, supported by proprietary technology and patents. The opportunity lies in the potential scalability and cost advantages of its platform, while the main risks center on scientific execution, commercialization, reliance on partnerships, and the need for ongoing funding until meaningful revenues emerge.

NEWS

November 13, 2025 · 4:30 PM UTC

eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today

Read more

November 13, 2025 · 4:15 PM UTC

eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff

Read more

November 10, 2025 · 5:00 PM UTC

eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST

Read more

October 30, 2025 · 4:10 PM UTC

CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference

Read more

October 29, 2025 · 5:40 PM UTC

CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference

Read more